Beyond lowering LDL cholesterol

被引:5
|
作者
Bayturan, Ozgur [1 ]
Utuk, Ozan [1 ]
Tuzcu, E. Murat [2 ]
机构
[1] Celal Bayar Univ, Tip Fak, Kardiyol Anabilim Dali, Manisa, Turkey
[2] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2011年 / 11卷 / 02期
关键词
Residual risk; LDL; atherogenic dyslipidemia; apolipoprotein B; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; VERY-LOW LEVELS; PHOSPHOLIPASE A(2); CARDIOVASCULAR EVENTS; HDL CHOLESTEROL; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; APOLIPOPROTEIN-B;
D O I
10.5152/akd.2011.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Compelling evidence from randomized controlled studies demonstrated the crucial role of lowering low-density lipoprotein cholesterol (LDL-C) in the prevention of vascular events. However, not all patients with low LDL-C levels show similar reduction in event rates. The residual risk factors associated with ongoing vascular events despite achieving low LDL-C levels remain to be elucidated. New data suggest that beyond statin therapy, inflammatory mediators, high non-HDL (high-density lipoprotein) cholesterol or apolipoprotein B, small dense LDL-C, type 2 diabetes mellitus, and lifestyle features may have impact on residual vascular risk. In this review, we discussed the significance of identifying these residual risk factors and developing new treatment strategies to further decrease vascular events. The importance of imaging arterial wall to evaluate the effect of various medical therapies has also stated. (Anadolu Kardiyol Derg 2011; 11: 163-7)
引用
收藏
页码:163 / 167
页数:5
相关论文
共 50 条
  • [21] Inclisiran (Leqvio) for LDL-Cholesterol Lowering
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1646): : 43 - 45
  • [22] Niacin is Major Drug for Lowering LDL - Cholesterol
    Murad, Shah
    Memon, M. Ashraf
    Channa, M. Aslam
    Kafil, Nighat
    Turab, S. Mohsin
    Bhurgri, Ghulam Rasool
    Rasheed, Shahzad
    Chohan, Raj Kumar
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2008, 2 (03): : 104 - 106
  • [23] Lowering LDL cholesterol -: How much is enough?
    Maerz, W.
    Grammer, T. B.
    INTERNIST, 2007, 48 (03): : 319 - +
  • [24] Clinical reality of lowering total and LDL cholesterol
    Frye, RL
    CIRCULATION, 1997, 95 (02) : 306 - 307
  • [25] Statins and LDL-cholesterol lowering: an overview
    Stroes, E
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 : S9 - S16
  • [26] Lowering LDL Cholesterol Is Good, but How and in Whom?
    Stone, Neil J.
    Lloyd-Jones, Donald M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (16): : 1564 - 1565
  • [27] NEW DRUGS FOR LOWERING LDL-CHOLESTEROL
    Badescu, Codruta
    Rezus, Elena
    Badescu, L.
    Dima, Nicoleta
    Rezus, C.
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (03): : 485 - 490
  • [28] LDL-cholesterol lowering and renal outcomes
    Waters, David D.
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (03) : 195 - 199
  • [29] LDL-cholesterol lowering: to be or not to be too low
    Duprez, Daniel
    Jacobs Jr, David R.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (12) : 1205 - 1206
  • [30] No limit to the benefits of LDL-cholesterol lowering
    Gregory B. Lim
    Nature Reviews Cardiology, 2015, 12 (8) : 444 - 444